Taneli Jouhikainen

Mirror Biologics Inc manufactures immune modulatory vaccines and therapeutics. The company is based in Tampa, FL. The company was founded in 2019 by Michael Har-Noy. Michael Har-Noy has been the CEO since 2019.

Akela Pharma, Inc. operates as a drug development company, which develops and manufactures pharmaceutical formulations and drugs. The company operates as a specialty contract pharmaceutical formulation developer and clinical and commercial drug manufacturer for proprietary drug products through its wholly-owned subsidiary, PharmaForm LLC, a pharmaceutical intellectual property development company. It provides specialty contract services in the area of pharmaceutical dosage form development, preclinical, scale-up, clinical and commercial supply manufacturing, focusing on controlled release and bioavailability enhancement technologies, such as hot melt extrusion, spray drying and liquid filled capsules. Akela Pharma was founded on November 15, 1988 and is headquartered in Austin, TX.

LAB International (LAB Pharma and LAB Research) is an integrated drug development company. LAB Pharma is focused on the growing multi-billion dollar inhalation market. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, and growth hormone deficiencies

AKELA Pharma Oy, founded in 2000, develops inhalers, inhalation products, and related production technology. The company is based in Turku, Finland. AKELA Pharma was acquired by LAB International, Inc. on January 12, 2004 for $1.85 million.

Part of Bayer AG, Leiras is a Finnish company that specializes in medicinal chemicals and botanical products. The private company is located in Finland. Leiras was acquired by Bayer Schering Pharma AG on July 01, 1996 for $262.11 million.

Aravas, Inc. develops innovative drugs for the treatment of serious and life-threatening conditions. It develops dry powder formulations for various therapeutic molecules, including antibiotics, corticosteroids, nucleic acids, and insoluble and soluble molecules. The firm’s products include AeroVanc, an inhaled dry powder form of vancomycin in a capsule-based inhaler to treat methicillin-resistant staphylococcus aureus infections in patients with cystic fibrosis or other lung-compromising conditions; and AeroCort, a high performance inhaled corticosteroid product for the treatment of asthma in children. The company was founded by Cory Berkland, Chris Marich, Robert N. Neville, Taneli Jouhikainen, Chal Lenge and George Laurence in March 2007 and is headquartered in Austin, TX.